KOLMAR-BNH
23.8.2024 15:01:27 CEST | Business Wire | Press release
HemoHim, a health functional food developed by Kolmar BNH (KRX: 200130), is garnering significant attention in the global market thanks to its meticulous quality control measures throughout the entire process, starting with the stringent management of raw material origins.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823112347/en/
HemoHim G, produced by Kolmar BNH and distributed by Atomy is gaining a great popularity around the world (Image: Kolmar BNH)
HemoHim is Korea's first individually-approved health functional food designed to enhance immune function and alleviate fatigue. Developed by Kolmar BNH in 2006, it is formulated with domestic natural ingredients such as angelica gigas, cnidium officinale, and paeonia japonica. Distributed by Atomy, HemoHim is exported to about 20 countries, including the United States and China. Since its launch, it has generated over KRW 2 trillion in cumulative domestic and international sales, with exports surpassing USD 200 million.
HemoHim's nearly 20-year consumer preference is highly attributed to the "trust earned through rigorous quality control." Kolmar BNH, the manufacturer of HemoHim, maintains strict oversight over the cultivation of its primary raw materials—Korean angelica gigas Nakai, cnidium officinale, paeonia japonica—ensuring their safety. The company has established a dedicated food safety team to continuously share technology and provide education to raw material cultivating farms, while rigorously inspecting the safety, stability, and efficacy of these ingredients.
Furthermore, Kolmar BNH has enhanced its quality competitiveness by developing genetic testing methods to verify the country of origin, ensuring the prevention of contamination of primary raw materials with other species. In July, Kolmar BNH patented a genetic analysis method (SCAR Marker) that identifies the origin of Korean angelica gigas by recognizing specific genetic regions. Moreover, Kolmar BNH developed a genetic analysis method using PCR (polymerase chain reaction) analysis for cnidium officinalea and paeonia japonica and completed the patent registration process two years ago.
Safety was also the top priority for HemoHim G, a latest product targeting the global market. In April, Kolmar BNH published a study on HemoHim G in the SCIE-ranked journal ‘Toxicological Research,’ demonstrating its safety. Conducted according to OECD guidelines, the study holds significance not only in facilitating safety approvals in other countries but also in securing intellectual property rights with reliable results.
HemoHim G (Global) is the international version of HemoHim, Korea’s first individually-approved immune-boosting health supplement developed by Kolmar BNH over an eight-year period. The formulation has been tailored to comply with the food regulations of various countries, with adjustments made to raw materials and ingredient ratios. The product features angelica sinensis, ligusticum chuanxiong, paeonia lactiflora, all selected through rigorous provenance and quality control processes. Enhanced taste and aroma also make HemoHim G more appealing to a broader audience.
Kolmar BNH plans to continuously improve quality through ongoing research and development to support HemoHim's growth as a globally recognized brand.
"HemoHim, now established as a leading K-health functional food brand in the global market, is manufactured through an exhaustive quality control process,” A Kolmar BNH official said. “We will continue to conduct extensive research and development to further enhance product reliability.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240823112347/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 20261.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of Psychedelics” at 4:30pm ET. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resis
EMVCo Requests Feedback on Framework for Secure, Interoperable and Scalable Card-Based Agentic Payments1.9.2026 11:00:00 CEST | Press release
EMVCo – the technical body that creates and manages EMV® Specifications and programmes – has released a draft framework to help promote secure, interoperable and scalable card-based agentic payments. The framework provides a foundation for further industry engagement and potential specification development, with all interested stakeholders encouraged to provide their feedback on EMV® Agentic Payments – Framework for Specificationsby Wednesday 30 September. A key focus across the agentic commerce ecosystem is how to establish intent and determine that a consumer delegated authority to an AI agent to make a purchase on their behalf. Following industry input, EMVCo has focused on card-based agentic payment scenarios where intent needs to be managed over time, such as recurring purchases, cumulative budgets and post-transaction activities. These scenarios may require access to a shared intent ‘state’ that persists across multiple participants and their interactions. EMVCo has identified an
ChargePoint Accelerates European Growth Strategy with Appointment of John Saffrett as EVP and Managing Director, Europe1.9.2026 11:00:00 CEST | Press release
Saffrett brings more than 25 years of leadership experience in global mobility, fleet management, and digital transformationAppointment signals ChargePoint's commitment to accelerating European growth as the company targets increasing its European market and revenue share ChargePoint (NYSE: CHPT), a global leader in intelligent electrification and e-mobility, today announced the appointment of John Saffrett as Executive Vice President and Managing Director, Europe. In this role, Saffrett will be responsible for driving ChargePoint's growth strategy across European markets, overseeing sales, customer relationships, partnerships, and market expansion across the continent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901888806/en/ ChargePoint's EVP and Managing Director John Saffrett He has served as a member of the company’s Advisory Council since March 2026 and is a seasoned global mobility executive with more than 25 ye
Club Vita Launches German VitaCurves Model as Pension Risk Transfer Market Gathers Momentum1.9.2026 10:00:00 CEST | Press release
Address-based longevity model expands Club Vita's global suite of analytics to cover the UK, US, Canada, Netherlands and Germany Club Vita, an international leader in longevity data analytics, has launched a German calibration of its popular address-based longevity model, VitaCurves, further expanding its international footprint and supporting the growing pension risk transfer (PRT) market in Germany. The launch marks another milestone in Club Vita's international expansion and extends its suite of address-based mortality models, which already provides mortality insights in the UK, United States, Canada and the Netherlands. The German VitaCurvesDEU model is already being used by a leading insurer, helping to provide a more granular understanding of longevity risk across pension and insurance portfolios. VitaCurves uses granular location-based and socio-economic data to identify differences in mortality patterns between sub-populations, enabling insurers, pension funds and other stakeho
JEOL: Launch of the New Benchtop Scanning Electron Microscope “JCM-7000Plus NeoScope™”1.9.2026 09:30:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the benchtop scanning electron microscope (SEM) “JCM-7000Plus” and will begin sales on September 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825564112/en/ JCM-7000Plus NeoScope™ [Development Background] Benchtop scanning electron microscopes are increasingly used in fields including electrical and electronics, automotive and machinery, steel and metals, chemical and pharmaceuticals. They are utilized not only in research and development but also in manufacturing-related applications, such as quality control and product inspection. In addition, they are adopted in educational settings at middle and high schools as well as universities. Given these diverse applications, there is growing demand for improved operational efficiency, simpler and more automated operation, and enhanced observation, analysis, and measurement performance. To meet these needs, we have e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom